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Discriminating Bacterial and Viral Infection
Using a Rapid Host Gene Expression Test*
OBJECTIVES: Host gene expression signatures discriminate bacterial
and viral infection but have not been translated to a clinical test platform.
This study enrolled an independent cohort of patients to describe and validate a first-in-class host response bacterial/viral test.
DESIGN: Subjects were recruited from 2006 to 2016. Enrollment blood
samples were collected in an RNA preservative and banked for later testing. The reference standard was an expert panel clinical adjudication,
which was blinded to gene expression and procalcitonin results.
SETTING: Four U.S. emergency departments.
PATIENTS: Six-hundred twenty-three subjects with acute respiratory illness or suspected sepsis.
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INTERVENTIONS: Forty-five–transcript signature measured on the
BioFire FilmArray System (BioFire Diagnostics, Salt Lake City, UT) in ~45
minutes.
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MEASUREMENTS AND MAIN RESULTS: Host response bacterial/viral
test performance characteristics were evaluated in 623 participants (mean
age 46 yr; 45% male) with bacterial infection, viral infection, coinfection, or
noninfectious illness. Performance of the host response bacterial/viral test
was compared with procalcitonin. The test provided independent probabilities of bacterial and viral infection in ~45 minutes. In the 213-subject
training cohort, the host response bacterial/viral test had an area under the
curve for bacterial infection of 0.90 (95% CI, 0.84–0.94) and 0.92 (95%
CI, 0.87–0.95) for viral infection. Independent validation in 209 subjects
revealed similar performance with an area under the curve of 0.85 (95% CI,
0.78–0.90) for bacterial infection and 0.91 (95% CI, 0.85–0.94) for viral
infection. The test had 80.1% (95% CI, 73.7–85.4%) average weighted
accuracy for bacterial infection and 86.8% (95% CI, 81.8–90.8%) for viral
infection in this validation cohort. This was significantly better than 68.7%
(95% CI, 62.4–75.4%) observed for procalcitonin (p < 0.001). An additional cohort of 201 subjects with indeterminate phenotypes (coinfection
or microbiology-negative infections) revealed similar performance.
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CONCLUSIONS: The host response bacterial/viral measured using the
BioFire System rapidly and accurately discriminated bacterial and viral infection better than procalcitonin, which can help support more appropriate
antibiotic use.
KEY WORDS: bacterial infections; gene expression signatures;
pneumonia; point-of-care testing; sepsis; viral infections

A

cute respiratory illness (ARI) is the most common reason for acute
healthcare visits (1, 2). Patients with ARI are inappropriately treated
with antibacterials at high rates due to challenges in discriminating
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viral, bacterial, or noninfectious etiologies (3, 4).
Diagnostics that reliably discriminate bacterial and
viral etiologies in patients with ARI could improve
clinical management.
Currently available diagnostic strategies for ARI
largely focus on pathogen identification, which identifies a pathogen in only a minority of cases (5).
Depending on the type of pathogen assay, additional
limitations include long time to result, inability to discriminate infection from colonization, and the need
for a priori suspicion for the specific pathogen. In contrast, measuring the host response to infection offers
a complementary, unbiased strategy that overcomes
many of these limitations. Procalcitonin, a commonly
used host response marker, has exhibited mixed results
in discriminating bacterial from viral ARI etiologies
(6–8) and in guiding antibacterial use (9, 10). In contrast, recent studies have shown that peripheral blood
host gene expression accurately discriminates bacterial, viral, and noninfectious etiologies of ARI (11–17).
Host gene expression tests are commercially available
for noninfectious diseases such as oncology and transplant rejection (18, 19). Due to their complexity, these
tests are typically performed in referral laboratories and
require days to return results. Consequently, host gene
expression tests are not currently available for infectious
diseases, which require results at the point-of-need for
real-time clinical decision-making. Our study objectives
were to demonstrate the feasibility of developing a host
gene expression test that could be used at the point-ofneed and to demonstrate its ability to discriminate bacterial, viral, and noninfectious illness in a clinical cohort.
To achieve these objectives, we developed a first-in-class
research use only (RUO) test for the BioFire System to
quantify host gene expression for suspected infection.
This host response bacterial/viral (HR-B/V) test was
evaluated in a multisite study of patients presenting to
the emergency department (ED) with suspected infection of up to 28 days duration using clinical adjudication
as the reference standard. The findings presented here
demonstrate the feasibility of a rapid, point-of-need, host
response test that differentiates bacterial and viral illness.

MATERIALS AND METHODS
Study Design
Studies were approved by relevant Institutional Review
Boards and in accordance with the Declaration of
1652     www.ccmjournal.org

Helsinki. All subjects or their legally authorized representatives provided written informed consent. Patients
were enrolled by convenience sampling in four EDs
from 2006 to 2016: Duke University Medical Center
(Durham, NC), Durham VA Healthcare System
(Durham, NC), UNC Healthcare (Chapel Hill, NC),
and Henry Ford Hospital (Detroit, MI). This was done
as part of three consecutively executed observational
studies: Community-Acquired Pneumonia and Sepsis
Outcome Diagnostics (CAPSOD) (ClinicalTrials.gov
NCT00258869) (20–22), the Community-Acquired
Pneumonia and Sepsis Study (CAPSS), and the Rapid
Diagnostics in Categorizing Acute Lung Infection
(RADICAL). Patients were eligible for CAPSOD and
CAPSS if they were greater than or equal to 6 years with
a known or suspected infection of less than 28 days
duration and exhibited two or more systemic inflammatory response syndrome criteria (23). RADICAL
enrolled patients age greater than or equal to 2 years
with ARI of less than 28 days duration. Prior antimicrobial exposure was not exclusionary. ARI was defined as having at least two qualifying symptoms or
one qualifying symptom and at least one qualifying
vital sign abnormality. Qualifying symptoms included
headache, rhinorrhea, nasal congestion, sneezing, sore
throat, itchy/watery eyes, conjunctivitis, cough, shortness of breath, sputum production, chest pain, and
wheezing. Qualifying vital sign abnormalities included
heart rate greater than or equal to 90 (or ≥ 110 for children 2–6 yr old), respiratory rate greater than or equal
to 20, and temperature greater than or equal to 38.0ºC
or less than or equal to 36.0ºC. There were 1,274 subjects enrolled in CAPSOD, 1,320 in CAPSS and 944
in RADICAL. Subjects were selected from this larger
pool based on the availability of a PAXgene Blood RNA
sample (Qiagen, Hilden, Germany) and confirmatory
microbiology (with the exception of suspected bacterial and suspected viral cases). In suspected cases where
no microbiological etiology was identified, consecutive
subjects were selected for inclusion in this study.
Diagnostic Reference Standard
In the absence of a gold standard for bacterial/viral
discrimination, we performed retrospective adjudications as previously described (20, 24). Clinician
adjudicators had experience managing patients with
ARI defined by subspecialty training in hospital
medicine, emergency medicine, infectious diseases,
October 2021 • Volume 49 • Number 10
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or pulmonary/critical care medicine or by greater
than 2 years of postgraduate clinical experience in
that field. Two independent adjudications were performed greater than 28 days after enrollment using
the full medical record, supplemental etiology testing, and case report forms but not host response test
nor procalcitonin results. This avoided incorporation
bias and allowed procalcitonin to be used as an independent comparator. Supplemental testing included
the BinaxNOW Streptococcus pneumoniae urinary
antigen test (Alere, Waltham, MA) and a multiplex viral respiratory pathogen panel (ResPlex V2.0,
Qiagen; Respiratory Viral Panel, Luminex, Austin,
TX; or Respiratory Pathogen Panel, Luminex). For
discordant adjudications, a consensus panel of at least
three adjudicators entered the final adjudication by
consensus or majority vote.
BioFire Testing
A custom, RUO BioFire test was designed to
measure 45 host messenger RNA (mRNA) transcripts (Supplementary Table 1, http://links.lww.com/
CCM/G446) that were previously shown to be differentially expressed in viral, bacterial, or noninfectious
causes of ARI (Supplementary Methods, http://links.
lww.com/CCM/G446) (16, 25). A larger pool of targets
was initially selected. The assays included in the final
HR-B/V test were selected through iterative evaluations and selection for robust performance (strong linearity and low variability in quantitative reporting)
using BioFire nested, multiplex polymerase chain reaction (PCR) chemistry. The test included internal and endogenous normalization controls, selected for their low
coefficients of variation (< 0.1). Upon loading 100 µL
of PAXgene-preserved blood (~27 µL whole blood
volume) into the disposable pouch, automated sample extraction, nucleic acid purification, reverse transcription
(RT), and two stage (multiplexed-nested) real-time PCR
were performed by the BioFire FilmArray Instrument
(Supplementary Fig. 1, http://links.lww.com/CCM/
G446). All assays were tested in duplicate within each
pouch in case of assay failure although failure rates were
low in both the discovery (0.18%) and validation (0.13%)
cohorts. The real-time PCR curve quantification results,
as expressed in quantification cycle (Cq) values, were
collected for each assay for each sample. The Cq value is
a semiquantitative measure of target abundance defined
by the PCR cycle number at which a target is detected.
Critical Care Medicine

Therefore, lower values (i.e., fewer PCR cycles) indicate a
greater abundance of the target in a sample.
Statistical Analysis
Normalized target expression values were used to
build two independent sparse logistic regression models: viral versus nonviral infection and bacterial versus
nonbacterial infection (26). The two probabilities are
independent, which allows for the identification of
coinfection (i.e., both positive) or no infection (i.e., both
negative). To generate these probabilities, the BioFire
Cq values were used to build a logistic regression model
trained on subjects with known phenotype. The regularization variable of the model and performance metrics
were estimated using nested leave-one-out cross-validation (LOOCV), where the internal LOOCV was used
for the regularization variable and the outer LOOCV for
performance estimates including area under the curve
(AUC), positive percent agreement (PPA), and negative
percent agreement (NPA) (27). PPA is calculated in the
same manner as sensitivity, whereas NPA is calculated in
the same manner as specificity. The terms PPA and NPA
were used instead of sensitivity and specificity given the
use of a reference standard rather than a gold standard,
as recommended for the clinical performance evaluation of molecular diagnostic tests (28). After training
the model, variables were fixed and applied to independent cohorts. Thresholds for the bacterial and viral
tests (27.5% and 41.7%, respectively) were calculated to
optimize the average weighted accuracy (AWA) (29).
AWA is a pragmatic metric of diagnostic yield or global
utility of a diagnostic test that integrates sensitivity and
specificity, accounts for disease prevalence within the
population, and accounts for the clinical implications of
false-positive and false-negative results. The AWA was
calculated assuming a 10–30% bacterial infection prevalence, 50–80% viral infection prevalence, r equals to
0.25 for bacterial classification, and r equals to 2 for viral
classification. Details regarding the development of the
AWA metric and how it specifically applies to this test
are described elsewhere (29). Comparison of HR-B/V to
procalcitonin was performed using the chi-square test.
Procalcitonin concentrations greater than or equal to
0.25 ng/mL indicated bacterial infection (10).
Additional details regarding study design, case definitions, procalcitonin measurement, transcript selection process, and statistical analysis are included in
the Supplementary Materials (http://links.lww.com/
CCM/G446).
www.ccmjournal.org
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curves for this and subsequent comparisons are shown
in Supplementary Figure 3 (http://links.lww.com/
Clinical Cohort
CCM/G446). The model trained in these 213 subjects
We enrolled 623 subjects at four EDs present- was then fixed and used for all subsequent tests. A
ing with suspected sepsis or ARI (Fig. 1). Of these, heatmap highlighting the contribution of each tran422 had microbiologically confirmed phenotypes script in the signature to discriminate bacterial, viral,
(Supplementary Table 2, http://links.lww.com/ and noninfectious illness is shown in Supplementary
CCM/G446) and were randomly assigned to training Figure 4 (http://links.lww.com/CCM/G446).
Validation Cohort. In the 209-subject valida(n = 213) or validation (n = 209) cohorts, so the numbers of bacterial, viral, and noninfectious illness cases tion cohort, the test had an AWA of 80.1% (95% CI,
were balanced (Table 1). The remaining 201 subjects 73.7–85.4%) for bacterial infection and 86.8% (95% CI,
(82 suspected bacterial infections, 83 suspected viral 81.8–90.8%) for viral infection (Fig. 2B and Table 2).
infections, and 36 coinfections) were tested but not in- The corresponding AUCs were 0.85 (95% CI, 0.78–
cluded in calculations of performance characteristics 0.90) and 0.91 (95% CI, 0.85–0.94), respectively.
Infection Site. To evaluate the test in specific clinical
due to the absence of a reliable reference standard.
subgroups, we combined the training and validation
groups to increase the evaluable sample size. Whereas
Classification
all viral infections were respiratory in nature, the bacteTraining Cohort. Thresholds for positive and negative rial infections included a variety of anatomic sites. The
test results were selected to maximize the AWA, which PPA for bacterial infection was 84% for respiratory tract
incorporates the clinical significance of false-positive (n = 50), 71% for urinary tract (n = 35), 86% for vasand false-negative errors (Supplementary Fig. 2, http:// cular device (n = 14), 75% for skin/soft tissue (n = 12),
links.lww.com/CCM/G446). Using nested LOOCV in 100% for intra-abdominal (n = 12), and 92% for other
the training cohort, the HR-B/V test had an AWA of sites (n = 12) (Supplementary Table 3, http://links.
83.3% (95% CI, 77.4–88.2%) for the identification of lww.com/CCM/G446).
bacterial infection and 85.9% (95% CI, 80.4–90.1%)
Procalcitonin. In the combined cohort of 422 subfor viral infection (Fig. 2A and Table 2). The corre- jects, the HR-B/V test was significantly better at dissponding AUCs were 0.90 (95% CI, 0.84–0.94%) and criminating bacterial from nonbacterial etiologies
0.92 (95% CI, 0.87–0.95), respectively. Precision-recall compared with procalcitonin (Fig. 2, C and D). This
was driven by a higher
PPA for the HR-B/V test
(82.2% vs 60.7% for procalcitonin; p < 0.001). NPA
for bacterial infection was
similar (81.2% for HR-B/V
vs 84.7% for procalcitonin;
p = 0.27). Whereas the
HR-B/V test distinguishes
viral from noninfectious
etiologies, procalcitonin
does not, which precluded
a comparison of the tests
for this purpose.
Confounders. We evaluated the impact of age,
sex, ethnicity, and illness
Figure 1. Experimental flow. The indeterminate phenotypes group was not used to calculate
severity (as defined by the
performance characteristics but used to demonstrate the distribution of host response bacterial/
need for hospitalization).

RESULTS

viral test results in these groups. ARI = acute respiratory illness.
1654     www.ccmjournal.org
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TABLE 1.

Subjects Characteristics
Coinfection
(n = 36)

Suspected
Bacterial
Infection
(n = 82)

Suspected
Viral
Infection
(n = 83)

47.4 (18.6)

46.1 (16.4)

47.2 (18.9)

35.3 (14.1)

100 (46.9)

96 (45.9)

12 (33.3)

49 (59.8)

23 (27.7)

317 (50.9)

110 (51.6)

97 (46.4)

25 (69.4)

53 (64.6)

32 (38.6)

Black

284 (45.6)

96 (45.1)

104 (49.8)

11 (30.6)

25 (30.5)

48 (57.8)

Other

22 (3.5)

7 (3.3)

8 (3.8)

0

4 (4.9)

3 (3.6)

Bacterial

135 (32.0)

68 (31.9)

67 (32.1)

Viral

183 (43.4)

92 (43.2)

91 (43.5)

Noninfection

104 (24.6)

53 (24.9)

51 (24.4)

236 (37.9)

84 (39.4)

79 (37.8)

19 (52.8)

41 (50.0)

13 (15.7)

Chronic lung disease

166 (26.6)

57 (26.8)

63 (30.1)

7 (19.4)

24 (29.3)

15 (18.1)

Chronic liver disease

14 (2.2)

5 (2.3)

6 (2.9)

2 (5.6)

0

1 (1.2)

Coronary artery disease

76 (12.2)

29 (13.6)

26 (12.4)

3 (8.3)

12 (14.6)

6 (7.2)

Diabetes

135 (21.7)

53 (24.9)

47 (22.5)

9 (25)

14 (17.1)

12 (14.5)

Dialysis

12 (1.9)

8 (3.8)

4 (1.9)

0

Heart failure

42 (6.7)

23 (10.8)

11 (5.3)

1 (2.8)

6 (7.3)

1 (1.2)

HIV infection

11 (1.8)

6 (2.8)

5 (2.4)

4 (11.1)

8 (9.8)

2 (2.4)

Hypertension

280 (44.9)

112 (52.6)

90 (43.1)

14 (38.9)

36 (43.9)

28 (33.7)

Immunosuppressive
therapy

62 (10.0)

24 (11.3)

25 (12.0)

2 (5.6)

7 (8.5)

4 (4.8)

Malignancy

59 (9.5)

23 (10.8)

25 (12.0)

2 (5.6)

7 (8.5)

2 (2.4)

304 (48.8)

118 (55.4)

107 (51.2)

23 (63.9)

51 (62.2)

5 (6.0)

Demographic and
Clinical Variables

Total
Cohort
(n = 623)

Age, yr, mean (sd)
Male sex, n (%)

Training
Cohort (n = 213)

Validation
Cohort
(n = 209)

46.1 (17.9)

48.6 (17.9)

280 (44.9)

White

Race, n (%)a

Etiology, n (%)b

Abnormal temperature,
n (%)c
Comorbidities, n (%)

Hospitalized, n (%)

0

0

Race was reported by participants.
Etiology is only defined in subjects who had a microbiologically confirmed pathogen. Those with coinfection, suspected bacterial, or
suspected viral etiologies were excluded from this calculation.
c
Abnormal temperature is defined as ≤ 35.5ºC or ≥ 38.0ºC.
a

b

This was done in the combined 422-subject cohort to
improve the ability to detect such differences although
the study was not powered for these analyses. There
were no statistically significant differences due to age,
Critical Care Medicine

sex, or ethnicity, but there was a higher accuracy among
nonhospitalized subjects compared with hospitalized
subjects (83.8% vs 74.2%; p = 0.02). (Supplementary
Table 4, http://links.lww.com/CCM/G446).
www.ccmjournal.org
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Figure 2. Classification performance. The test assigns each subject a probability of viral infection (y-axis) and bacterial infection (x-axis).
The vertical line is the threshold for bacterial infection (0.275), whereas the horizontal line is the threshold for viral infection (0.417). The top
left region is indicative of viral infection, bottom left indicates no infection, top right suggests bacterial/viral coinfection, and the bottom right
indicates bacterial infection. For (A) and (B), colors represent the adjudicated phenotype: blue = bacterial, yellow = noninfectious illness, red
= viral. A, Classification of 213 training cohort subjects. B, Classification of 209 validation cohort subjects. C, The probabilities of bacterial
infection (y-axis) as measured by the host response bacterial/viral (HR-B/V) test versus procalcitonin (PCT) (x-axis) are plotted for each
subject. The vertical line represents a PCT threshold of 0.25ng/mL. The horizontal line is the threshold for a positive bacterial HR-B/V test.
Subjects in the training cohort (n = 213) are represented by circles, whereas validation cohort subjects (n = 209) are represented by a plus.
Blue represents cases adjudicated as bacterial. Red represents cases adjudicated as nonbacterial (viral or noninfectious illness). The top
right region was identified as bacterial by both tests. The bottom left region represents a nonbacterial classification by both tests. D, Receiver
operating characteristic plot for bacterial versus nonbacterial infection using the HR-B/V test versus PCT in the training (discovery) and
validation cohorts. E, Classification of 36 subjects with bacterial/viral coinfection (superinfection). Red circles represent clinically suspected
cases of superinfection without microbiological confirmation. Blue circles represent microbiologically confirmed superinfection. F, 83
suspected viral infections (red circles), and 82 suspected bacterial infections (blue circles) are shown.
1656     www.ccmjournal.org
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TABLE 2.

Performance Characteristics of the Host Response Bacterial/Viral Test in the Training and
Validation Cohorts
Average
Weighted
Accuracy

Area
Under
the
Curve

Bacterial
infection

83.3
(77.4–
88.2)

0.90
(0.84–
0.94)

85.3
(75.8–
92.9)

81.4
(75.0–
86.8)

Viral infection

85.9
(80.4–
90.1)

0.92
(0.87–
0.95)

85.9
(78.1–
92.1)

Procalcitonin

77.1
(70.4–
83.0)

0.84
(0.76–
0.89)

Bacterial
infection

80.1
(73.7–
85.4)

Viral infection

Procalcitonin

Test Group

Likelihood
Ratio
Positive

Likelihood
Ratio
Negative

F1

Bayesian
Posttest
Probability

82.6
(77.5–
86.9)

4.6
(3.2–
6.8)

0.18
(0.09–
0.3)

0.758
(0.676–
0.829)

52.2
(44.0–
61.7)

86.0
(78.9–
90.9)

85.9
(80.8–
90.1)

6.1
(4.1–
10.0)

0.16
(0.09–
0.26)

0.840
(0.772–
0.892)

91.6
(87.3–
94.4)

67.6
(54.3–
77.6)

86.2
(79.0–
90.9)

80.3
(74.6–
85.4)

4.9
(3.1–
8.1)

0.38
(0.25–
0.52)

0.687
(0.579–
0.770)

53.9
(43.1–
67.4)

0.85
(0.78–
0.90)

79.1
(68.9–
87.9)

81.0
(73.6–
86.9)

80.4
(75.0–
85.6)

4.2
(2.9–
5.9)

0.26
(0.15–
0.41)

0.721
(0.626–
0.794)

49.9
(41.5–
58.9)

86.8
(81.8–
90.8)

0.91
(0.85–
0.94)

89.0
(81.4–
94.7)

84.7
(77.1–
90.5)

86.6
(81.8–
90.9)

5.8
(3.8–
9.4)

0.13
(0.07–
0.22)

0.853
(0.796–
0.901)

91.2
(87.4–
94.4)

68.7
(62.4–
75.4)

0.72
(0.62–
0.79)

53.7
(41.0–
65.3)

83.1
(76.5–
88.5)

73.7
(66.7–
79.4)

3.2
(2.1–
4.99)

0.56
(0.43–
0.71)

0.567
(0.463–
0.667)

43.5
(33.7–
54.6)

Negative
Positive
Percent
Overall
Percent
Agreement Agreement Accuracy

Training cohort

Validation cohort

All values are presented with a 95% CI. The Bayesian post-test probability represents the expected posttest probability for a pretest
probability with a uniform prevalence distribution in the range of 0.1–0.3 for bacterial infection and 0.5–0.8 for viral infection.

Alternative Reporting Schemes
There is no standardized approach to reporting results
of composite biomarkers. Thus far, we applied a single
threshold to determine the presence or absence of disease, so every tested subject receives a potentially actionable result. However, values close to the thresholds
may have greater uncertainty. To account for this uncertainty, we evaluated the impact of two alternative
reporting schemes: probability quartiles and inclusion
of an equivocal zone.
Infection Score Quartiles. This scheme provides
greater ability to rule-in or rule-out bacterial and viral
infection for subjects in the highest and lowest quartiles, respectively. Probability thresholds defined by
training cohort quartiles were applied to the validation
group. Those thresholds were well calibrated in both
Critical Care Medicine

cohorts (Supplementary Fig. 5, http://links.lww.com/
CCM/G446). For bacterial infection diagnosis, the
lowest quartile had a PPA of 100% and 94.0% (likelihood ratio negative 0.09) in the training and validation cohorts, respectively (Supplementary Table 5,
http://links.lww.com/CCM/G446 and Supplementary
Fig. 6, http://links.lww.com/CCM/G446). The highest quartile for bacterial infection in the training and
validation cohorts had a NPA of 92.4% (likelihood
ratio positive [LR+] 5.04) and 90.1% (LR+ 4.39), respectively. The HR-B/V test performed better with respect to viral infection with a PPA of 96.7% in both
the training and validation cohorts as well as a NPA
of 98.3% and 94.9%, respectively. Additional results
are shown in Supplementary Table 5 (http://links.lww.
com/CCM/G446) and Supplementary Figure 6 (http://
links.lww.com/CCM/G446).
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TABLE 3.

Comparison of Result Reporting Schemes
Single Threshold

Quartiles

Equivocal Zone

Test Group

PPA

NPA

% Cohort

PPA

NPA

% Cohort

PPA

NPA

% Cohort

Training cohort—bacterial vs
nonbacterial model

85.3

81.4

100

100

92.4

50

85.4

86.2

85

Validation cohort—bacterial vs 79.1
nonbacterial model

81.0

100

94.0

90.1

50

83.2

83.1

88

Training cohort—viral vs
nonviral model

85.9

86.0

100

96.7

98.3

50

84.5

92.3

85

Validation cohort—viral vs
nonviral model

89.0

84.7

100

96.7

94.9

50

81.5

91.8

85

NPA = negative percent agreement, PPA = positive percent agreement.
We evaluated three different reporting schemes. The single threshold scheme uses a single numerical threshold to determine whether
a subject has a bacterial infection in the bacterial versus nonbacterial model or a viral infection in the viral versus nonviral model. This
single threshold allows for all subjects to be classified. The quartile scheme uses multiple thresholds to assign subjects into probability
bands. The reported PPA and NPA values focus on the top and bottom quartiles, therefore representing 50% of the cohort. The equivocal zone model allows for a probability band in which no call can be made. The equivocal zone thresholds for bacterial versus nonbacterial and viral versus nonviral classification were selected to exclude no more than 15% of the cohort.

Equivocal Zone. An equivocal zone decreases the
number of subjects with an actionable result, but the diagnostic confidence is higher for subjects above or below
the zone’s thresholds. We defined probability thresholds
for both bacterial (0.18–0.37) and viral (0.26–0.47) infection that maximized AWA in the training cohort
while assigning less than 15% of subjects to the equivocal zone. Scatter plots of subjects in training and validation cohorts for both the bacterial and viral models
are presented along with a graphical representation of
the scheme in Supplementary Figure 7 (http://links.
lww.com/CCM/G446). Incorporating an equivocal
zone, the HR-B/V test had an AUC of 0.92 and AWA of
87% in the training cohort, as compared to an AUC of
0.86 and AWA of 83% in the validation cohort. For viral
infection diagnosis, the training cohort had an AUC of
0.94 and AWA of 91% as compared to an AUC of 0.91
and 87% AWA in the validation cohort. Confusion matrices are presented in Supplementary Table 6 (http://
links.lww.com/CCM/G446). A comparison of results
for the three schemes (single threshold, quartiles, and
equivocal zone) is shown in Table 3.
Coinfection
We identified 36 cases of respiratory superinfection defined as a bacterial infection arising during or after an
antecedent viral infection. In 12 cases, both bacterial
1658     www.ccmjournal.org

and viral pathogens were microbiologically confirmed.
In the remaining 24 subjects, a bacterial superinfection
was clinically suspected but not microbiologically confirmed. Using the first reporting scheme where a single
threshold determined the presence or absence of bacterial and viral infection, the HR-B/V test identified a bacterial infection in all 12 microbiologically confirmed cases
(100%) as compared to 75% for procalcitonin (p = 0.07)
(Fig. 2E). Among the 24 cases of suspected superinfection, 11 were identified as having a viral infection (n = 11;
45.8%), five (20.8%) had a bacterial host response, five
(20.8%) had both bacterial and viral responses, and
three (12.5%) were negative for infection. Procalcitonin
was greater than or equal to 0.25 ng/mL in 10 of 24 suspected superinfection cases (41.7%).
We then evaluated how many subjects in the training
and validation cohorts adjudicated as having a monomicrobial infection would have been diagnosed with
coinfection using the HR-B/V test. Among the 135 bacterial infections, eight (5.9%) also demonstrated a host
response to viral infection. Among the 183 viral infections, 12 (6.6%) also demonstrated a host response to
bacterial infection.
Suspected Infection
A host-based approach might offer the greatest benefit to patients with ARI but no positive microbiology.
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In this study, these subjects had clinical syndromes
compatible with bacterial or viral infection based on
expert panel adjudication but no identified pathogen.
Of the 82 suspected bacterial cases, 61 (74.4%) were
classified as bacterial or bacterial/viral coinfection. An
additional 10 (12.2%) were classified as viral, whereas
11 cases (13.4%) were classified as neither (Fig. 2F).
Procalcitonin was greater than or equal to 0.25 ng/mL
in 38 cases (46.3%). In the group of 83 suspected viral
cases, 30 (36.1%) had a viral host response, 31 (37.3%)
had a bacterial host response, three (3.6%) had both
bacterial and viral responses, and 19 (22.9%) were negative for both. Procalcitonin was less than 0.25 ng/mL
in 77 cases (92.8%).

DISCUSSION
The overlap in symptoms due to bacterial, viral, and
noninfectious disease leads to diagnostic uncertainty
and inappropriate antimicrobial use. Pathogen detection tests play an important clinical role but are insufficient to make a diagnosis in the majority of ARI
cases. In the current study, we built upon our previous
findings that host gene expression accurately discriminates bacterial, viral, and noninfectious disease (16, 25).
Beyond simply validating the signature, this study
provides proof of principle that a complex host gene
expression signature based on machine learning algorithms can be translated to a clinical platform and validated in an independent test cohort. The HR-B/V test
was superior to procalcitonin both with respect to the
identification of bacterial infection and the ability to
discriminate viral from noninfectious disease. We also
showed that blood serves as an accurate biosensor for
bacterial infection at multiple different anatomic sites
of infection. Furthermore, the HR-B/V test provided
clear results even in complex or ambiguous cases such
as coinfection or suspected infection.
Host gene expression signatures have been identified for multiple conditions including coronary artery disease, oncology, transplant rejection, and sepsis
(18, 19, 30, 31). However, the utility of these tests is
limited by a turnaround time of many hours to days
due to their high complexity. In this study, we used the
widely available BioFire system to measure host gene
expression of 45 host mRNA biomarkers with results
available in about 45 minutes. The biological roles and
associated pathways for these targets have previously
been described (16, 25). HR-B/V overall accuracy
Critical Care Medicine

was similar to that previously reported despite using
a much smaller signature and translation to an integrated, sample-to-answer platform: 87% using microarray (25), 88% using Taqman Low-Density Array
RT-PCR (24), and 80–87% in this study (depending on
the subgroup).
Multiple studies have described host response signatures to discriminate viral and bacterial infection
(14, 16, 32–42). In most cases, these signatures focus
only on subjects with bacterial or viral infection
without adequately accounting for the possibility of
noninfectious illness. To address this limitation, we
used a composite of two signatures: bacterial versus
nonbacterial (i.e., viral or noninfectious) illness and
viral versus nonviral (i.e., bacterial or noninfectious)
illness. The possible outputs of this composite signature are therefore bacterial infection, viral infection,
coinfection, or no infection. Although this scheme
increases generalizability, it comes at the expense of
a lower overall test accuracy. First, the test must distinguish three categories rather than just two, increasing the opportunities for classification errors. Second,
there is a high degree of overlap in the host’s response
to bacterial infection and noninfectious illness. Third,
the AWA statistical approach minimizes false-negative
bacterial errors, which carry the greatest risk of patient
harm. In so doing, it maximizes the test’s sensitivity for
bacterial infection at the expense of specificity. These
factors may explain the lower overall accuracy among
hospitalized subjects, which were more likely to have
either bacterial or noninfectious etiologies.
Most biomarker tests measure a single analyte and
typically report the value as a concentration (e.g., procalcitonin in ng/mL). However, multianalyte host response
assays convert raw measurements (e.g., Cq for mRNA)
into a probability function or composite score. Presently,
there are no standardized ways to report such results.
Previously described schemes include the use of single
thresholds to provide results for all tested patients, quartiles/bands, and equivocal zones (24, 25, 43–45). In this
study, we compared results for all three schemes. Our
findings do not specify which approach is best but highlight the challenges in reporting results of composite biomarker tests. Furthermore, different clinical scenarios
(e.g., screening vs diagnosis) might warrant different
approaches.
The HR-B/V test identified all cases of microbiologically confirmed bacterial superinfection. However,
www.ccmjournal.org
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some patients with superinfection but no confirmed
bacterial pathogen demonstrated a viral host response.
This suggests that secondary or persistent viral infections may be responsible for some suspected superinfections. Along these lines, we observed a significant
number of patients with suspected (microbiologynegative) bacterial infections who instead had a viral
host response. Without microbiological confirmation,
these could be adjudication errors, test errors, or perhaps infections due to atypical bacterial pathogens
such as mycoplasma.
The best currently available clinical laboratory test
for bacterial versus viral discrimination is procalcitonin. A meta-analysis demonstrated that procalcitoninguided algorithms reduced antibiotic use and improved
patient outcomes (46). However, this result was not
reproduced in the U.S.-based Procalcitonin Antibiotic
Consensus Trial (ProACT) (9). Furthermore, the ability
of procalcitonin to discriminate bacterial from viral
infection has been limited: 55% sensitivity and 76%
specificity in patients with community-acquired pneumonia (8). Procalcitonin performed better in this study
(60.7% sensitivity and 84.7% specificity) although not
as well as host gene expression, consistent with prior
observations (25, 35, 38, 47, 48). Despite these low performance characteristics, procalcitonin is widely used
to guide antibacterial use. This underscores that a diagnostic test need not have perfect or even exceptional
accuracy to be clinically useful, desirable as that may
be. If a biomarker is to be the sole determinant of treatment in the absence of additional clinical data, then
performance characteristics should be sufficiently high
after accounting for the clinical consequences of false
positives and false negatives. However, when used as
an adjunct to other clinical information, biomarkers
can be clinically useful and actionable even with lower
accuracies (e.g., procalcitonin, WBC counts, fever). It
is noteworthy that our reference standard in this study
was clinical adjudication, which is known to be inaccurate. As such, we would not expect (nor desire) performance metrics that are too good to be true. In such
a situation, the test would have done little more than
perfectly matched an imperfect comparator.
Among this study’s limitations are that it was not
powered to detect differences due to demographics
such as age, race, and ethnicity. A peripheral blood
host gene expression test may not perform as expected in patients with profound abnormalities in
1660     www.ccmjournal.org

their peripheral leukocyte counts or distributions such
as neutropenia. A recent evaluation of host gene expression in subjects with immunocompromising conditions revealed slightly lower but still clinically useful
performance (49). We did not assess the kinetics of the
host response and are therefore unable to assess response to treatment. Perhaps, the greatest limitation is
the absence of a gold standard to define the presence of
bacterial or viral infection. We therefore relied on expert adjudication, which is imperfect despite being the
best available standard. Last, a clinical utility study will
be necessary to demonstrate that such a test actually
mitigates antibiotic overuse without compromising
(and perhaps improving) patient outcomes.

CONCLUSIONS
This study demonstrates the first translation of a host
gene expression signature for the diagnosis of bacterial and viral infection. In doing so, we demonstrate
the feasibility of quantifying the host transcriptional
response for real-time clinical decision-making,
opening a new pathway for test development in multiple clinical domains. The HR-B/V test was superior
to procalcitonin.
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